Merz unveils 'Make Your Mark' campaign

Share this article:
A new patient advocacy campaign called “Make Your Mark” was launched April 14 on behalf of Merz Pharmaceuticals, maker of orphan drug Xeomin, a botulinum toxin type A free from accessory proteins. The online effort features the testimonials of national spokespeople—including 2010 Mrs. North Carolina, Dawn Brinkley, and opera singer, writer and actress, Hallie Neil—as well as the personal experiences of people living with cervical dystonia or blepharospasm.
Though the drug has been used abroad since 2005, Xeomin was approved in the US in 2010 for the treatment of adults with cervical dystonia to decrease the severity of abnormal head position and neck pain, and to treat abnormal spasms of the eyelids in adults who have had prior treatment with Botox. Administered as an injectible, Xeomin works to decrease muscle activity, which allows muscles to function more normally for patients diagnosed with either of these conditions.
The web-based campaign was developed by New York agency Medical Dynamics (the public relations AOR), in close partnership with Merz Pharmaceuticals, according to the company's director of marketing, Robert Yanez. This campaign will continue into 2012 and is one of “several initiatives designed to raise awareness of cervical dystonia and blepharospasm and encourage patient dialogue” by Merz Pharmaceuticals, says Yanez.
On the overall objective of the campaign, Yanez explains: “With the help of patient advocates, ‘Make Your Mark' celebrates the inspirational stories of people living with blepharospasm or cervical dystonia, also known as spasmodic torticollis, and aims to raise awareness of these often debilitating conditions.”
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.